Understanding the Genetics of Age-Related Macular Degeneration: Gregory S. Hageman, PhD

Video

The executive director of the Steele Center for Translational Medicine at the Moran Eye Center discussed the research his team has been conducting in AMD.

“We have teams that are pushing towards both [factor H on chromosome 1 and ARMS2 and HTRA1 on chromosome 10]. And I would say we have a very robust understanding of what the disease process is what's happening in the back of the eye, we have a lot of clinical correlates, we understand that these are very much different biological diseases [that cause AMD] and the sad part is a lot of patients will have some mix of both. So down the line, we'll have to think about therapies.”

Loci in chromosome 10 and chromosome 1 have previously been identified as important in the role of developing age-related macular degeneration (AMD). Recent research into the HTRA1 and ARMS2 genes in the chromosome 10 locus have elucidated the role of these genes in developing AMD.

To learn more about the implications of these findings, GeneTherapyLive spoke with Brandi. L Williams, PhD, research director, and Gregory S. Hageman, PhD, executive director, Steele Center for Translational Medicine, both from the John A. Moran Eye Center. 

Williams and Hageman discussed the paper they recently published in PNAS which was the culmination of 15 years of research, providing some background on the Moran Center and previous research in AMD.

REFERENCE
Williams BL, Seager NA, Gardiner JD, et al. Chromosome 10q26–driven age-related macular degeneration is associated with reduced levels of HTRA1 in human retinal pigment epithelium. PNAS. 2021;118(30) e2103617118. doi:10.1073/pnas.2103617118

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
© 2025 MJH Life Sciences

All rights reserved.